LODELYCS Trademark

Trademark Overview


On Monday, February 3, 2025, a trademark application was filed for LODELYCS with the United States Patent and Trademark Office. The USPTO has given the LODELYCS trademark a serial number of 99026775. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, July 22, 2025. This trademark is owned by Merck Sharp & Dohme B.V.. The LODELYCS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of bone, cardiovascular, central nervous system, dermatological, endocrine, hematological, hepatological, immunological, gastrointestinal, genitourinary, gynecological, metabolic, musculoskeletal, nephrological, neurological, oncological, ophthalmic, psychiatric, pulmonary, renal, respiratory, and urological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of autoimmune diseases, asthma, cancer and tumors, chronic cough, diabetes, hypertension, insomnia, intestinal infections, skin disorders, and urinary incontinence; Inhalers filled with pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Anti-infectives; Anti-inflammatories; Antiparasitics; Antivirals; Human vaccine preparations
lodelycs

General Information


Serial Number99026775
Word MarkLODELYCS
Filing DateMonday, February 3, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, July 22, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of bone, cardiovascular, central nervous system, dermatological, endocrine, hematological, hepatological, immunological, gastrointestinal, genitourinary, gynecological, metabolic, musculoskeletal, nephrological, neurological, oncological, ophthalmic, psychiatric, pulmonary, renal, respiratory, and urological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of autoimmune diseases, asthma, cancer and tumors, chronic cough, diabetes, hypertension, insomnia, intestinal infections, skin disorders, and urinary incontinence; Inhalers filled with pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Anti-infectives; Anti-inflammatories; Antiparasitics; Antivirals; Human vaccine preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 3, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMerck Sharp & Dohme B.V.
Party Type10 - Original Applicant
Legal Entity Type26 - NOT AVAILABLE
AddressHaarlem 2031 BN
NL

Trademark Events


Event DateEvent Description
Monday, February 3, 2025NEW APPLICATION ENTERED
Monday, February 3, 2025APPLICATION FILING RECEIPT MAILED
Monday, July 14, 2025ASSIGNED TO EXAMINER
Monday, February 3, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 14, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, July 14, 2025SUSPENSION LETTER WRITTEN
Monday, July 14, 2025LETTER OF SUSPENSION E-MAILED
Tuesday, July 22, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 22, 2025ASSIGNED TO LIE
Tuesday, July 22, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 24, 2025PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, July 24, 2025TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, July 15, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED